Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more
Beijing SL Pharmaceutical Co Ltd (002038) - Total Assets
Latest total assets as of September 2025: CN¥6.03 Billion CNY
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) holds total assets worth CN¥6.03 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing SL Pharmaceutical Co Ltd - Total Assets Trend (2001–2024)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Beijing SL Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Beijing SL Pharmaceutical Co Ltd's total assets of CN¥6.03 Billion consist of 41.6% current assets and 58.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.9% |
| Accounts Receivable | CN¥121.44 Million | 2.0% |
| Inventory | CN¥246.33 Million | 4.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥1.20 Billion | 20.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing SL Pharmaceutical Co Ltd's current assets represent 41.6% of total assets in 2024, a decrease from 51.0% in 2001.
- Cash Position: Cash and equivalents constituted 6.9% of total assets in 2024, up from 4.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 13.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 20.0% of total assets.
Beijing SL Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Beijing SL Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Beijing SL Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Beijing SL Pharmaceutical Co Ltd generates 0.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Beijing SL Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Beijing SL Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.37 | 10.78 | 7.01 |
| Quick Ratio | 10.48 | 9.62 | 6.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.38 Billion | CN¥ 2.00 Billion | CN¥ 1.89 Billion |
Beijing SL Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing SL Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -4.8% |
| Total Assets | CN¥5.98 Billion |
| Market Capitalization | $524.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing SL Pharmaceutical Co Ltd's assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Beijing SL Pharmaceutical Co Ltd's assets decreased by 4.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Beijing SL Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual total assets of Beijing SL Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.98 Billion | -4.76% |
| 2023-12-31 | CN¥6.28 Billion | +6.84% |
| 2022-12-31 | CN¥5.88 Billion | +2.00% |
| 2021-12-31 | CN¥5.76 Billion | +6.78% |
| 2020-12-31 | CN¥5.39 Billion | +3.25% |
| 2019-12-31 | CN¥5.22 Billion | +4.74% |
| 2018-12-31 | CN¥4.99 Billion | +8.79% |
| 2017-12-31 | CN¥4.59 Billion | +12.34% |
| 2016-12-31 | CN¥4.08 Billion | +8.50% |
| 2015-12-31 | CN¥3.76 Billion | +13.33% |
| 2014-12-31 | CN¥3.32 Billion | +22.38% |
| 2013-12-31 | CN¥2.71 Billion | +22.35% |
| 2012-12-31 | CN¥2.22 Billion | +27.68% |
| 2011-12-31 | CN¥1.74 Billion | +39.05% |
| 2010-12-31 | CN¥1.25 Billion | +22.43% |
| 2009-12-31 | CN¥1.02 Billion | +29.33% |
| 2008-12-31 | CN¥788.52 Million | +34.41% |
| 2007-12-31 | CN¥586.63 Million | +27.09% |
| 2006-12-31 | CN¥461.61 Million | +13.72% |
| 2005-12-31 | CN¥405.91 Million | +4.13% |
| 2004-12-31 | CN¥389.83 Million | +156.75% |
| 2003-12-31 | CN¥151.83 Million | +47.64% |
| 2002-12-31 | CN¥102.84 Million | +33.33% |
| 2001-12-31 | CN¥77.13 Million | -- |